Poly-ε-Caprolactone Intravitreous Devices: An In Vivo Study

Silva-Cunha, Armando; Fialho, Sílvia Ligório; Naud, Marie‐Christine; Behar‐Cohen, Francine

doi:10.1167/iovs.08-2969

Cited by 46 publications

(29 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Fialho et al also developed poly-e-caprolactone (PCL) implants containing dexamethasone (Fialho et al, 2008;Fialho et al, 2009). These implants released dexamethasone concentrations in vitro, indicating their potential for suppressing several inflammatory processes.…”

Section: Biodegradable Implants In the Treatment Of Uveitismentioning

confidence: 99%

Implants as drug delivery devices for the treatment of eye diseases

Silva

Fialho

Siqueira³

et al. 2010

Braz. J. Pharm. Sci.

View full text Add to dashboard Cite

The treatment of diseases affecting the posterior segment of the eye is limited by the difficulty in transporting effective doses of drugs to the vitreous, retina, and choroid. Topically applied drugs are poorly absorbed due to the low permeability of the external ocular tissues and tearing. The blood-retina barrier limits drug diffusion from the systemic blood to the posterior segment, thus high doses of drug are needed to maintain therapeutic levels. In addition, systemic side effects are common. Intraocular injections could be an alternative, but the fast flowing blood supply in this region, associated with rapid clearance rates, causes drug concentration to quickly fall below therapeutic levels. To obtain therapeutic levels over longer time periods, polymeric sustained-drug release systems implanted within the vitreous are being studied for the treatment of vitreoretinal disorders. These systems are prepared using different kinds of biodegradable or non-biodegradable polymers. This review aims to demonstrate the main characteristics of these drug delivery implants and their potential for clinical application.Uniterms: Implants/biodegradation. Drugs/delivery systems. Drugs/prolonged delivery systems. Pharmaceutical technology.O tratamento de doenças do segmento posterior do olho é limitado pela dificuldade no transporte de doses efetivas de fármacos para o vítreo, retina e coróide. Os fármacos aplicados topicamente são pouco absorvidos por causa da baixa permeabilidade dos tecidos oculares externos e ao lacrimejamento. Embora a administração sistêmica seja capaz de transportar fármacos para o segmento posterior do olho, as barreiras hemato-aquosa e hematorretiniana dificultam a absorção e, normalmente, são necessárias doses elevadas, as quais estão geralmente associadas a potenciais efeitos adversos. Injeções intravitreais são capazes de transportar fármacos para o segmento posterior do olho, mas é uma técnica invasiva, pouco tolerada pelos pacientes e apresenta riscos de infecções oculares e danos aos tecidos. Visando a obtenção de níveis terapêuticos adequados de fármacos no segmento posterior do bulbo do olho por longos períodos, sistemas de liberação poliméricos implantados diretamente no vítreo estão sendo investigados para o tratamento de várias doenças vítreo-retinianas. Esses implantes podem ser preparados a partir de diferentes polímeros biocompatíveis, biodegradáveis ou não-biodegradáveis. Nesta revisão, as principais características destes implantes transportadores de fármacos são descritas, expondo suas potencialidades de aplicação clínica.Unitermos: Implantes oculares/biodegradação. Fármacos/sistemas de liberação. Fármacos/ Fármacos/ ação prolongada. Tecnologia farmacêutica.

show abstract

Section: Biodegradable Implants In the Treatment Of Uveitismentioning

confidence: 99%

Implants as drug delivery devices for the treatment of eye diseases

Silva

Fialho

Siqueira³

et al. 2010

Braz. J. Pharm. Sci.

View full text Add to dashboard Cite

show abstract

“…As dexamethasone is released, the polymer slowly degrades into carbon dioxide and water. 40 Since the implant dissolves completely, sequential implants can be placed into the eye over time without a need for surgical removal. Animal studies showed that the implants were well tolerated, the release of dexamethasone was gradual, and biodegradation was slow.…”

Section: Corticosteroid Implantsmentioning

confidence: 99%

Clinical Review: Update on Treatment of Inflammatory Macular Edema

Norel

Rothová

2010

Ocular Immunology and Inflammation

View full text Add to dashboard Cite

The aim of this review is to summarize the recent developments in the treatment of inflammatory macular edema (ME). Inflammatory ME represents a major cause of visual loss in uveitis and its adequate management is crucial for the maintenance of useful vision in patients with uveitis. Recent studies favor early treatment of inflammatory ME, even in patients with full visual acuity. After recapitulating the standard treatment modalities for inflammatory ME the authors address novel corticosteroid implants. They review the literature on the efficacy of anti-VEGF agents for inflammatory ME and point out their beneficial, but transient effects. Further, they present recent data on the value of systemic biologics in uveitic ME and evaluate the effectiveness of vitrectomy. Finally, they propose an algorithm for the treatment of inflammatory ME and point out that the individual risk-benefit ratio, especially with systemic immunosuppressive therapy, should always be considered.

show abstract

“…Release of antibiotics, like gentamicin sulfate (Chang et al, 2008), minocycline (Kyun et al, 1990), amikacin Prabu et al, 2006), gatifloxacin (El-Kamel & Baddour, 2007), and dexamethasone (Silva-Cunha et al, 2009), from PCL-PLA or PLA matrices, has been studied for applications in conditions like osteomyelitis, periodontitis, and as implants for intravitreous administration. Hormonal delivery has also been studied using PCL, primarily due to its long degradation time.…”

Section: Introductionmentioning

confidence: 99%

Novel poly-DL-lactide-polycaprolactone copolymer based flexible drug delivery system for sustained release of ciprofloxacin

Waknis

Jonnalagadda

2010

Drug Delivery

View full text Add to dashboard Cite

This research evaluated 7525DLPCL for soft flexible drug delivery systems. The effect of ciprofloxacin hydrochloride (CIP) loading at three levels (10, 20, and 30%), on thermo-mechanical properties was studied. CIP release was monitored for 12 weeks. Addition of CIP to 7525DLPCL caused an increase in compressive modulus of 7525DLPCL. CIP release was found to be sigmoidal with two phenomena (apart from a minor burst) contributing to release-diffusion and later diffusion plus erosion. An increased burst was observed with greater CIP loading and the majority of CIP (> 70%) was released as an effect of diffusion plus erosion. Additional factors, like the effect of CIP particle size, had no significant effect on drug release. Change in the implant shape from a cylinder (5 mm diameter; 3 mm thickness) to disc (6 mm diameter, 0.5 mm thickness) also failed to show a significant impact on drug release. Erosion of 7525DLPCL is a major contributing factor towards this release and other factors like shape of implants and particle size of drug have little effect on CIP release. Such flexible drug delivery systems offer new avenues for long-term skeletal drug delivery of antibiotics for conditions like osteomyelitis or periodontitis.

show abstract

Poly-ε-Caprolactone Intravitreous Devices: An In Vivo Study

Abstract: This study demonstrates the feasibility and tolerance of intravitreous PCL drug delivery systems, which can offer a wide range of applications for intraocular drug delivery because of their controlled and prolonged release over months or even years.

Cited by 46 publications

References 35 publications

Implants as drug delivery devices for the treatment of eye diseases

Implants as drug delivery devices for the treatment of eye diseases

Clinical Review: Update on Treatment of Inflammatory Macular Edema

Novel poly-DL-lactide-polycaprolactone copolymer based flexible drug delivery system for sustained release of ciprofloxacin

Contact Info

Product

Resources

About